{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Sections', 'Initial wording', 'Amended or new wording', 'Reason/Justification', 'Reasons', 'for change', 'for', 'substantial', 'amendment', 'Appendix K', 'Neutrophils value', 'Neutrophils value', 'Change: neutrophils value', 'Change of', 'General Guidance for the', 'Neutrophils <1500/mm\u00b3 or according to ethnic group', 'Neutrophils <1000/mm\u00b3 according to ethnic group', 'for Sanofi follow up of', 'safety', 'follow up of laboratory', 'abnormalities', 'monitoring', 'abnormalities by Sanofi', 'parameter', 'Reasons for change: To', 'adjust the neutrophil count', 'defining neutropenia in the', 'study population age group', '(pediatric trial)', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 178']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Amendment protocol 01 dated 10-Mar-2017', 'FeNO results', 'In section: 9.4.2.2', 'Rationale:', '-', 'Blinding of FeNO results as described in Section 9.4.2.2 was determined to be', 'operationally not feasible. Therefore, the FeNO value will not be blinded to', 'investigators or site personnel, as well as patient(s)/parent(s)/caregiver(s)/lega', 'guardian(s).', 'Live attenuated vaccines', 'In section(s): Sections 7.2.3 and 8.8.1', 'Rationale:', '-', 'In order to clearly define the interval between live (attenuated) vaccines administration', 'and IMP administration and be consistent with other dupilumab trials, an Exclusion', 'Criterion E27 will be added to clarify that live (attenuated) vaccines are not allowed', 'within 4 weeks before the baseline visit. Section 8.8.1 Prohibited Concomitant', 'medication will be rewritten to clarify that live (attenuated) vaccines are allowed in the', 'screening period if taken at least 4 weeks prior to baseline visit.', 'PAQLQ Domains', 'In section: 9.2.2.4.2', 'Rationale:', '-', 'The number of domains was incorrectly described as 4, instead of 3.', 'PAQLQ (S)-IA Periodicity', 'In section(s): Clinical Trial Summary (Secondary Endpoints Efficacy) and Section 11.4.2', 'Rationale:', '-', 'The periodicity of PAQLQ(S)-IA was incorrectly marked as Weeks 2, 4, 8, 12, 24, 36,', '52. Its correct periodicity is at Weeks 12, 24, 36, 52, 64.', 'Property of the Sanofi Group - strictly confidential', 'Page 179', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Inhaled Corticosteroids Doses', 'In section: Appendix A', 'Rationale:', '-', 'Medium and high doses of beclometasone dipropionate (CFC and HFA) and', 'budesonide (DPI) are inconsistent with GINA Guidelines 2015. Therefore, the table', 'will be updated with the correct values for medium and high dose of beclometasone', 'dipropionate (CFC and HFA) and budesonide (DPI).', 'PEF meter', 'In Section: 9.2.2.2.1', 'Rationale:', '-', 'AM and PM time frames were extended by 2 hours, ie, to end at 11:59 AM and', '11:59 PM, respectively.', '-', 'Albuterol/salbutamol or levoalbuterol/levosalbutamol reliever medication are the only', 'medications to be withheld for at least 6 hours before PEF measurement, if possible.', 'IMP compliance check', 'In section: 10.1.10', 'Rationale:', '-', 'IMP compliance must be verified at these visits. This information is missing in the', 'protocol.', 'Informed Assent Form (IAF) for girls who started menstruating', 'In section: 1.2 and 12.2', 'Rationale:', '-', 'Clarified that as soon as the investigator is notified that the first menses of a female', 'patient have occurred (at any time during this study) a separate IAF must be obtained', 'from such female patients at the earliest visit to the site. This information is missing in', 'the protocol.', 'Patient monitoring', 'In section: 8.1.4', 'Property of the Sanofi Group - strictly confidential', 'Page 180', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}